

OCT 08 2008

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCEUnder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid  
OMB control number.Substitute for form 1449/PTO  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 30

## Complete if Known

Application Number	09/899059
Filing Date	07/06/2001
First Named Inventor	Craig A. Rosen
Art Unit	1647
Examiner Name	Guo-Liang Yu

Attorney Docket Number 075977-0122

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US-4,002,531-	01-11-1977	ROYER	
	A2	US-4,179,337-	12-18-1979	DAVIS ET AL.	
	A3	US-4,433,092-	02-21-1984	NEMETH	
	A4	US-4,444,887-	04-24-1984	HOFFMANN	
	A5	US-4,474,893-	10-02-1984	READING	
	A6	US-4,631,211-	12-23-1986	HOUGHTEN	
	A7	US-4,676,980-	06-30-1987	SEGAL ET AL.	
	A8	US-4,708,781-	11-24-1987	VANDER	
	A9	US-4,714,681-	12-22-1987	READING	
	A10	US-4,716,111-	12-29-1987	OSBAND ET AL.	
	A11	US-4,741,900-	05-03-1988	ALVAREZ ET AL.	
	A12	US-4,816,397-	03-28-1989	BOSS ET AL.	
	A13	US-4,816,567-	03-28-1989	CABILLY ET AL.	
	A14	US-4,873,191-	10-10-1989	WAGNER ET AL.	
	A15	US-4,925,648-	05-15-1990	HANSEN ET AL.	
	A16	US-4,946,778-	08-07-1990	LADNER ET AL.	
	A17	US-4,980,286-	12-25-1990	MORGAN ET AL.	
	A18	US-4,994,560-	02-19-1991	KRUPER ET AL.	
	A19	US-5,112,946-	05-12-1992	MAIONE	
	A20	US-5,122,464-	06-16-1992	WILSON ET AL.	
	A21	US-5,194,392-	03-16-1993	GEYSEN	
	A22	US-5,223,409-	06-29-1993	LADNER ET AL.	
	A23	US-5,225,539-	07-06-1993	WINTER	
	A24	US-5,258,498-	11-02-1993	HUSTON ET AL.	
	A25	US-5,274,119-	12-28-1993	FRAZIER ET AL.	
	A26	US-5,314,995-	05-24-1994	FELL ET AL.	
	A27	US-5,336,603-	08-09-1994	CAPON ET AL.	
	A28	US-5,342,604-	08-30-1994	WILSON ET AL.	
	A29	US-5,349,052-	09-20-1994	DELGADO ET AL.	
	A30	US-5,349,053-	09-20-1994	LANDOLFI	
	A31	US-5,359,046-	10-25-1994	CAPON ET AL.	
	A32	US-5,399,349-	03-21-1995	PAUNESCU ET AL.	
	A33	US-5,403,484-	04-04-1995	LADNER ET AL.	
	A34	US-5,413,923-	05-09-1995	KUCHERLAPATI ET AL.	
	A35	US-5,427,908-	06-27-1995	DOWER ET AL.	
	A36	US-5,428,139-	06-27-1995	KIEFER ET AL.	
	A37	US-5,435,990-	07-25-1995	CHENG ET AL.	
	A38	US-5,436,146-	07-25-1995	SHENK ET AL.	
	A39	US-5,441,050-	08-15-1995	THURSTON ET AL.	
	A40	US-5,447,851-	09-05-1995	BEUTLER ET AL.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
(use as many sheets as necessary)				Attorney Docket Number	075977-0122
Sheet	2	of	30		

U.S. PATENT DOCUMENTS			
		Document Number	
A41	US-5,460,959-	10-24-1995	MULLIGAN ET AL.
A42	US-5,463,575-	10-31-1995	WHITE
A43	US-5,474,981-	12-12-1995	LEDER ET AL.
A44	US-5,478,925-	12-26-1995	WALLACH ET AL.
A45	US-5,480,971-	01-02-1996	HOUGHTEN ET AL.
A46	US-5,489,425-	02-06-1996	KRUPER ET AL.
A47	US-5,505,931-	04-09-1996	PRIBISH
A48	US-5,516,637-	05-14-1996	HUANG ET AL.
A49	US-5,530,101-	06-25-1996	QUEEN ET AL.
A50	US-5,545,806-	08-13-1996	LONBERG ET AL.
A51	US-5,565,332-	10-15-1996	HOOGENBOOM ET AL.
A52	US-5,569,825-	10-29-1996	LONBERG ET AL.
A53	US-5,571,698-	11-05-1996	LADNER ET AL.
A54	US-5,573,920-	11-12-1996	RANDLE
A55	US-5,580,717-	12-03-1996	DOWER ET AL.
A56	US-5,580,859-	12-03-1996	FELGNER ET AL.
A57	US-5,585,089-	12-17-1996	QUEEN ET AL.
A58	US-5,601,819-	02-11-1997	WONG ET AL.
A59	US-5,605,793-	02-25-1997	STEMMER
A60	US-5,612,460-	03-18-1997	ZALIPSKY
A61	US-5,622,929-	04-22-1997	WILLNER ET AL.
A62	US-5,625,126-	04-29-1997	LONBERG ET AL.
A63	US-5,633,425-	05-27-1997	LONBERG ET AL.
A64	US-5,641,670-	06-24-1997	TRECO ET AL.
A65	US-5,643,575-	07-01-1997	MARTINEZ ET AL.
A66	US-5,652,361-	07-29-1997	SIMON ET AL.
A67	US-5,658,727-	08-19-1997	BARBAS ET AL.
A68	US-5,661,016-	08-26-1997	LONBERG ET AL.
A69	US-5,693,622-	12-02-1997	WOLFF ET AL.
A70	US-5,696,239-	12-09-1997	WILSON ET AL.
A71	US-5,698,426-	12-16-1997	HUSE
A72	US-5,705,151-	01-06-1998	DOW ET AL.
A73	US-5,714,631-	02-03-1998	WILSON ET AL.
A74	US-5,733,743-	03-31-1998	JOHNSON ET AL.
A75	US-5,750,753-	05-12-1998	KIMAE ET AL.
A76	US-5,756,065-	05-26-1998	WILSON ET AL.
A77	US-5,766,883-	06-16-1998	BALLANCE ET AL.
A78	US-5,780,225-	07-14-1998	WIGLER ET AL.
A79	US-5,807,715-	09-15-1998	MORRISON ET AL.
A80	US-5,808,003-	09-15-1998	SUBRAMANIAN ET AL.
A81	US-5,811,097-	09-22-1998	ALLISON ET AL.
A82	US-5,811,238-	09-22-1998	STEMMER ET AL.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	3	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

U.S. PATENT DOCUMENTS				
		Document Number		
A83	US-5,814,318-	09-29-1998	LONBERG ET AL.	
A84	US-5,821,047-	10-13-1998	GARRARD ET AL.	
A85	US-5,830,721-	11-03-1998	STEMMER ET AL.	
A86	US-5,834,252-	11-10-1998	STEMMER ET AL.	
A87	US-5,837,458-	11-17-1998	MINSHULL ET AL.	
A88	US-5,876,969-	03-02-1999	FLEER ET AL.	
A89	US-5,885,793-	03-23-1999	GRIFFITHS ET AL.	
A90	US-5,916,771-	06-29-1999	HORI ET AL.	
A91	US-5,939,598-	08-17-1999	KUCHERLAPATI ET AL.	
A92	US-5,969,108-	10-19-1999	MCCAFFERTY ET AL.	
A93	US-5,985,660-	11-16-1999	GALY	
A94	US-6,075,181-	06-13-2000	KUCHERLAPATI ET AL.	
A95	US-6,114,598-	09-05-2000	KUCHERLAPATI ET AL.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
A96	WO-00/52028-A1	09-08-2000	HUMAN GENOME SCIENCES, INC.		
A97	WO-00/64465-A1	11-02-2000	HUMAN GENOME SCIENCES ET AL.		
A98	EP-0 171 496-B1	05-23-1993	RESEARCH DEVELOPMENT CORPORATION OF JAPAN		
A99	EP-0 173 494-A2	03-05-1986	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY		
A100	DE-196 39 601-A1	09-04-1997	BAYER AG		
A101	EP-0 239 400-B1	09-30-1987	MEDICAL RESEARCH COUNCIL		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	4	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A102	EP-0 282 317-A2	09-14-1988	AMGEN INC.		
	A103	EP-0 307 434-B2	03-22-1989	SCOTGEN BIOPHARMACEUTICALS, INC.		
	A104	EP-0 322 094-B1	02-12-1992	DELTA BIOTECHNOLOGY LIMITED		
	A105	EP-0 367 166-A1	05-09-1990	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	A106	EP-0 394 827-A1	10-31-1990	F. HOFFMAN-LA ROCHE AG		
	A107	EP-0 396 387-B1	11-07-1990	RESEARCH DEVELOPMENT FOUNDATION		
	A108	EP-0 399 816-B1	12-20-1995	MERCK & CO., INC.		
	A109	EP-0 401 384-A1	12-12-1990	KIRIN-AMGEN, INC.		
	A110	EP-0 413 622-B1	02-20-1991	RHONE-POULENC RORER S.A.		
	A111	EP-0 439 095-A2	07-31-1991	BRISTOL-MYERS SQUIBB CO.		
	A112	EP-0 506 477-B1	09-30-1992	MERCK & CO., INC.		
	A113	EP-0 519 596-A1	12-23-1992	MERCK & CO., INC.		
	A114	EP-0 592 106-B1	04-13-1994	IMMUNOGEN INC.		
	A115	EP-0 682 110-A1	11-15-1995	CHIRON CORP.		
	A116	WO-86/01533-A1	03-13-1986	CELLTECH LIMITED		
	A117	WO-86/05807-A1	10-09-1986	CELLTECH LIMITED		
	A118	WO-87/01130-A1	02-26-1987	STAUFFER CHEMICAL CO.		
	A119	WO-87/02671-A1	05-07-1987	INTERNATIONAL GENETIC ENGINEERING, INC.		
	A120	WO-87/04462-A1	07-30-1987	CELLTECH LIMITED ET AL.		
	A121	WO-89/01036-A1	02-09-1989	CELLTECH LIMITED		
	A122	WO-89/02036-A1	03-09-1989	UPAT GMBH & CO.		
	A123	WO-89/10404-A1	11-02-1989	CELLTECH LIMITED		
	A124	WO-89/12624-A1	12-28-1989	CETUS CORPORATION		
	A125	WO-90/02809-A1	03-22-1990	PROTEIN ENGINEERING CORP.		
	A126	WO-90/11092-A1	10-04-1990	VICAL, INC., ET AL.		
	A127	WO-90/13649-A1	11-15-1990	GENENTECH, INC.		
	A128	WO-91/00360-A1	01-10-1991	MEDAREX, INC.		
	A130	WO-91/06570-A1	05-16-1991	THE UNIVERSITY OF MELBOURNE		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 30

**Complete if Known**

Application Number	09/899059
Filing Date	07/06/2001
First Named Inventor	Craig A. Rosen
Art Unit	1647
Examiner Name	Guo-Liang Yu
Attorney Docket Number	075977-0122

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A131	WO-91/06657-A1	05-16-1991	CELLTECH LIMITED		
	A132	WO-91/09967-A1	07-11-1991	CELLTECH LIMITED		
	A133	WO-91/10737-A1	07-25-1991	MOLECULAR AFFINITIES CORP.		
	A134	WO-91/10741-A1	07-25-1991	CELL GENESYS, INC.		
	A135	WO-91/14438-A1	10-03-1991	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK		
	A136	WO-92/01047-A1	01-23-1992	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED		
	A137	WO-92/05793-A1	04-16-1992	MEDAREX, INC.		
	A138	WO-92/06180-A1	04-16-1992	UNIVRSITY OF CONNECTICUT		
	A139	WO-92/06194-A1	04-16-1992	CONSIGLIO NAZIONALE DELLE RICERCHE		
	A140	WO-92/08495-A1	05-29-1992	ABBOTT BIOTECH, INC.		
	A141	WO-92/08802-A1	05-29-1992	CETUS CORPORATION		
	A142	WO-92/18619-A1	10-29-1992	THE SCRIPPS RESEARCH INSTITUTE		
	A143	WO-92/22324-A1	12-22-1992	XOMA CORPORATION		
	A144	WO-92/22635-A1	12-23-1992	UNIVERSITY OF CONNECTICUT ET AL.		
	A145	WO-93/11236-A1	06-10-1993	MEDICAL RESEARCH COUNCIL ET AL.		
	A146	WO-93/14188-A1	07-22-1993	THE REGENTS OF THE UNIVERSITY OF MICHIGAN		
	A147	WO-93/17715-A1	09-16-1993	UNIVERSITY OF OF TEXAS SYSTEM, BOARD OF REGENTS ET AL.		
	A148	WO-93/20221-A1	10-14-1993	ALEXANDER YOUNG		
	A149	WO-93/21232-A1	10-28-1993	RESEARCH DEVELOPMENT FOUNDATION		
	A150	WO-93/25788-A1	12-23-1993	HOPPE AG		
	A151	WO-94/08598-A1	04-28-1994	ADVANCED TISSUE SCIENCES, INC.		
	A152	WO-94/12649-A1	06-09-1994	GENZYME CORPORATION		
	A153	WO-94/12650-A1	06-09-1994	TRANSKARYOTIC THERAPIES, INC.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	6	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A154	WO-95/06058-A1	03-02-1995	ROYAL FREE HOSPITAL SCHOOL OF MEDICINE		
	A155	WO-95/15982-A1	06-15-1995	GENZYME CORP.		
	A156	WO-95/20401-A1	08-03-1995	TRUSTEES OF BOSTON UNIVERSITY		
	A157	WO-96/04388-A1	02-15-1996	SMITHKLINE BEECHAM PLC, ET AL.		
	A158	WO-96/26736-A1	09-06-1996	LUDWIG INSTITUTE FOR CANCER RESEARCH ET AL.		
	A159	WO-96/29411-A1	09-26-1996	TRANSKARYOTIC THERAPIES, INC.		
	A160	WO-96/33735-A1	10-31-1996	CELL GENESYS, INC.		
	A161	WO-96/34095-A1	10-31-1996	HUMAN GENOME SCIENCES, INC.		
	A162	WO-96/34096-A1	10-31-1996	CELL GENESYS, INC.		
	A163	WO-96/39515-A1	12-12-1996	HUMAN GENOME SCIENCES, INC.		
	A164	WO-97/03394-A1	01-30-1997	ITT INDUSTRIES LIMITED		
	A165	WO-97/33899-A1	09-18-1997	HUMAN GENOME SCIENCES, INC.		
	A166	WO-97/33904-A1	09-18-1997	HUMAN GENOME SCIENCES, INC., ET AL.		
	A167	WO-97/34911-A1	09-25-1997	HUMAN GENOME SCIENCES, INC.		
	A168	WO-98/02543-A1	01-22-1998	CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.		ABS.
	A169	WO-98/06842-A1	02-19-1998	SCHERING CORP.		
	A170	WO-98/07832-A1	02-26-1998	LUDWIG INSTITUTE FOR CANCER RESEARCH ET AL.		
	A171	WO-98/07880-A1	02-26-1998	HUMAN GENOME SCIENCES, INC.		
	A172	WO-98/11779-A1	03-26-1998	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA		
	A173	WO-98/16654-A1	04-23-1998	JAPAN TOBACCO, INC.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	7	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A174	WO-98/18921-A1	05-07-1998	HUMAN GENOME SCIENCES, INC.		
	A175	WO-98/24893-A1	06-11-1998	ABGENIX, INC.		
	A176	WO-98/30693-A2	07-16-1998	HUMAN GENOME SCIENCES, INC.		
	A177	WO-98/32466-A1	07-30-1998	POLYMASC PHARACEUTICALS PLC		
	A178	WO-98/32856-A1	07-30-1998	HUMAN GENOME SCIENCES, INC., ET AL.		
	A179	WO-98/41629-A1	09-24-1998	HUMAN GENOME SCIENCES, INC.		
	A180	WO-98/46645-A1	10-22-1998	PETER KUFER ET AL.		
	A181	WO-98/49305-A1	11-05-1998	AMGEN INC.		
	A182	WO-98/50433-A1	11-12-1998	ABGENIX, INC.		
	A183	WO-98/54202-A1	12-03-1998	HUMAN GENOME SCIENCES, INC.		
	A184	WO-98/56892-A1	12-17-1998	HUMAN GENOME SCIENCES, INC.		
	A185	WO-99/04813-A1	02-04-1999	BRIGHAM & WOMEN'S HOSPITAL, INC. ET AL.		
	A186	WO-99/23105-A1	05-14-1999	HUMAN GENOME SCIENCES, INC.		
	A187	WO-98/30694	07-16-1998	HUMAN GENOME SCIENCES, INC.		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
	A188	"Production of Antibody-Producing Hybridomas in Rodent Systems," pgs. 563-587 (1978).				
	A189	A. ASHKENAZI et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," Proc. Natl. Acad. Sci. USA, Vol. 88, Dec. 1991, pgs. 10535-10539.				

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	09/899059	
(use as many sheets as necessary)			Filing Date	07/06/2001	
Sheet	8	of	30	First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A190	A. BOUT et al., "Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium," Human Gene Therapy, Vol. 5, (1994), pgs. 3-10.	
	A191	A. CREASEY et al., "Biological Effects of Recombinant Human Tumor Necrosis Factor and its Novel Muteins on Tumor and Normal Cell Lines," Cancer Research, Vol. 47, Jan. 1, 1987, pgs. 145-149.	
	A192	A. CUENDA et al., "SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1," FEBS Letters, Vol. 364, (1995), pgs. 229-233.	
	A193	A. D. MILLER et al., "Improved Retroviral Vectors for Gene Transfer and Expression," BioTechniques, Vol. 7, No. 9, (1989), pgs. 980-990.	
	A194	A. D. MILLER et al., "Use of Retroviral Vectors for Gene Transfer and Expression," Methods in Enzymology, Vol. 217, pgs. 580-599.	
	A195	A. D. MILLER, "Retrovirus Packaging Cells," Human Gene Therapy, Vol. 1, (1990), pgs. 5-14.	
	A196	A. JOLIOT et al., "Antennapedia homeobox peptide regulates neural morphogenesis," Proc. Natl. Acad. Sci. USA, Vol. 88, March 1991, pgs. 1864-1868.	
	A197	A. KARSAN, "Tumor Necrosis Factor and Endothelial Cell Death," TCM, Vol. 8, No. 1, (1998), pgs. 19-24.	
	A198	A. MASTRANGELI et al., "Diversity of Airway Epithelial Cell Targets for In Vivo Recombinant Adenovirus-mediated Gene Transfer," The Journal of Clinical Investigation, Vol. 91, Jan. 1993, pgs. 225-234.	
	A199	A. NISONOFF, "Idiotypes: Concepts and applications," Journal of Immunology, Vol. 147, No. 8, Oct. 5, 1991, pgs. 2429-2438.	
	A200	A. PATZ, "Clinical and Experimental Studies on Retinal Neovascularization," American Journal of Ophthalmology, Vol. 94, No. 6, Dec. 1982, pgs. 715-743.	
	A201	A. S. CARVER et al., "Transgenic Livestock as Bioreactors: Stable Expression of Human alpha-1-Antitrypsin by a Flock of Sheep," Bio/Technology, Vol. 11, Nov. 1993, pgs. 1263-1270.	
	A202	A. SKERRA et al., "Assembly of a Functional Immunoglobulin Fv Fragment in Escherichia coli," SCIENCE, Vol. 240, (1988), pgs. 1038-1041.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	9	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A203	A. TRAUNECKER et al., "Soluble CD4 molecules neutralize human immunodeficiency virus type 1," NATURE, Vol. 331, Jan. 7, 1988, pgs. 84-86.		
	A204	A. TUTT et al., "Trispecific F(ab')3 Derivatives that use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells," The Journal of Immunology, Vol. 147, No. 1, July 1, 1991, pgs. 60-69.		
	A205	B. A. JAMESON et al., "The antigenic index: a novel algorithm for predicting antigenic determinants," CABIOS, Vol. 4, No. 1, (1988), pgs. 181-186.		
	A206	B. ABDALLAH et al., "Non-viral gene transfer: Applications in developmental biology and gene therapy," Biol. Cell, Vol. 85, (1995), pgs. 1-7.		
	A207	B. BEUTLER et al., "The Biology of Cachectin/TNF-A Primary Mediator of the Host Response," Ann. Rev. Immunol., Vol. 7, (1989), pgs. 625-655.		
	A208	B. C. CUNNINGHAM et al., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," SCIENCE, Vol. 244, (1989), pgs. 1081-1085.		
	A209	B. DENG et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," Blood, Vol. 92, No. 6, Sept. 1998, pgs. 1981-1988.		
	A210	B. DÉRIJARD et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras that Binds and Phosphorylates the c-Jun Activation Domain," Cell, Vol. 76, March 25, 1994, pgs. 1025-1037.		
	A211	B. H. KOLLER et al., "Inactivating the Beta-2-microglobulin locus in mouse embryonic stem cells by homologous recombination," Proc. Natl. Acad. Sci. USA, Vol. 86, November 1989, pgs. 8932-8935.		
	A212	B. LEWIN, Genes, second edition, John Wiley & Sons, (1985).		
	A213	B. SALMONS et al., "Targeting of Retroviral Vectors for Gene Therapy," Human Gene Therapy, Vol. 4, (1993), pgs. 129-141.		
	A214	B. SCHWARTZ et al., "Gene transfer by naked DNA into adult mouse brain," Gene Therapy, Vol. 3, No. 4, (1996), pgs. 405-411.		
	A215	B. TERMAN et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," Biochemical and Biophysical Research Communications, Vol. 187, No. 3, Sept. 30, 1992, pgs. 1579-1586.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	10	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A216	B. W. ZANKE et al., "The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat," Current Biology, Vol. 6, No. 5, (1996), pgs. 606-613.			
	A217	C. A. KETTLEBOROUGH et al., "Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments," Eur. J. Immunol., Vol. 24 (1994), pgs. 952-958.			
	A218	C. CHOTHIA et al., "Structural Determinants in the Sequences of Immunoglobulin Variable Domain," J. Mol. Biol., Vol. 278 (1998), pgs. 457-479.			
	A219	C. D. SAUDEK et al., "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," The New England Journal of Medicine, Vol. 321, No. 9, Aug. 1989, pgs. 574-579.			
	A220	C. DELGADO et al., "The uses and properties of PEG-linked proteins," Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 9, Issue 1, (1992), pgs. 249-304.			
	A221	C. E. WALSH et al., "Gene Therapy for Human Hemoglobinopathies," Proceedings of the Society for Experimental Biology and Medicine, Vol. 204, No. 3, Dec. 1993, pgs. 289-300.			
	A222	C. M. PEARSON et al., "Experimental Production of Arthritis in Rats," Ann. Rheum. Dis., Vol. 15, (1956), pgs. 379-380.			
	A223	C. M. PEARSON et al., "Studies of Polyarthritis and Other Lesions Induced in Rats by Injection of Mycobacterial Adjuvant. I. General Clinical and Pathologic Characteristics and Some Modifying Factors," Arthritis Rheum., Vol. 2, (1959), pgs. 440-459.			
	A224	C. R. BEBBINGTON et al., "High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker," Bio/Technology, Vol. 10, Feb. 1992, pgs. 169-175.			
	A225	C. REINHARD et al., "Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2," The EMBO Journal, Vol. 16, No. 5, (1997), pgs. 1080-1092.			
	A226	C. V. JOHNSON et al., "A Simple, Rapid Technique for Precise Mapping of Multiple Sequences in Two Colors Using a Single Optical Filter Set," GATA, Vol. 8, No. 2, (1991), pgs. 75-76.			
	A227	C. V. JOHNSON et al., "Fluorescent Detection of Nuclear RNA and DNA: Implications for Genome Organization," Methods in Cell Biology, Vol. 35, (1991), pgs. 73-99.			
	A228	C. W. LO, "Transformation by Iontophoretic Microinjection of DNA: Multiple Integrations Without Tandem Insertions," Molecular and Cellular Biology, Vol. 3, No. 10, Oct. 1983, pgs. 1803-1814.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
(use as many sheets as necessary)				Attorney Docket Number	075977-0122
Sheet	11	of	30		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A229	Clinical Pharmacy, Vol. 12, No. 7, July 1993, pgs 488-505.			T <sup>6</sup>
	A230	Current Protocols in Human Genetics, "Vectors for Gene Therapy," Chapter 12, (2007), pgs. 12.0.1- 13.10.06			
	A231	Current Protocols in Immunology, "Cytokines and Their Cellular Receptors," Chapter 6, (1991), pgs. 6.0.1-6.30.8.			
	A232	D. B. SMITH et al., "Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene, Vol. 67, (1988), pgs. 31-40.			
	A233	D. BENNETT et al., "Kinetic Characterization of the Interaction of Biotinylated Human Interleukin 5 with an Fc Chimera of its Receptor alpha Subunit and Development of an ELISA Screening Assay using Real-Time Interaction Biosensor Analysis," Journal of Molecular Recognition, Vol. 8, (1995), pgs. 52-58.			
	A234	D. BRUTLAG et al., "Improved sensitivity of biological sequence data base searches," CABIOS, Vol. 6, No. 3, 1990, pgs. 237-245.			
	A235	D. BRYANT et al., "Cardiac Failure in Transgenic Mice with Myocardial Expression of Tumor Necrosis Factor-alpha," Basic Science Reports, April 14, 1998, pgs. 1375-1381.			
	A236	D. C. ROBBINS et al., "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients," DIABETES, Vol. 36, July 1987, pgs. 838-841.			
	A237	D. D. WALTMAN et al., "Choroidal Neovascularization Associated with Choroidal Nevi," American Journal of Ophthalmology, Vol. 85, No. 5, (1978), pgs. 704-710.			
	A238	D. GOEDDEL et al., "Synthesis of human fibroblast interferon by E. coli," Nucleic Acids Research, Vol. 8, No. 18, (1980); pgs. 4057-4074.			
	A239	D. GOOD et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin," Proc. Natl. Acad. Sci. USA, Vol. 87, Sept. 1990, pgs. 6624-6628.			
	A240	D. L. STEMPLE et al., "Isolation of a Stem Cell for Neurons and Glia from the Mammalian Neural Crest," Cell, Vol. 71, Dec. 1992, pgs. 973-985.			
	A241	D. R. BURTON et al., "Human Antibodies from Combinatorial Libraries," Advances in Immunology, Vol. 57 (1994), pgs. 191-280.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	12	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A242	D. R. THOMSEN et al., "Promoter-regulatory region of the major immediate early gene of human cytomegalovirus," Proc. Natl. Acad. Sci. USA, Vol. 81, February 1984, pgs. 659-663.			
	A243	D. RON et al., "Expression of Biologically Active Recombinant Keratinocyte Growth Factor," The Journal of Biological Chemistry, Vol. 268, No. 4, Feb. 5, 1993, pgs. 2984-2988.			
	A244	D. SIDRANSKY et al., "Identification of P53 Gene Mutations in Bladder Cancers and Urine Samples," SCIENCE, Vol. 252, May 3, 1991, pgs. 706-709.			
	A245	D. W. LEUNG et al., "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen," SCIENCE, Vol. 246, Dec. 8, 1989, pgs. 1306-1309.			
	A246	D. W. NICHOLSON et al., "Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis," NATURE, Vol. 367, July 6, 1995, pgs. 37-43.			
	A247	D. WILSON et al., "JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells," Eur. J. Immunol., Vol. 26, (1996), pgs. 989-994.			
	A248	D.Y. YOON et al., "Antibodies to Domains II and III of the IL-1 Receptor Accessory Protein Inhibit IL-1-Beta Activity But Not Binding: Regulation of IL-1 Responses is Via Type I Receptor, Not the Accessory Protein," The Journal of Immunology, Vol. 160, (1998), pgs. 3170-3179.			
	A249	E. A. PADLAN, "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties," Molecular Immunology, Vol. 28, No. 4/5, (1991), pgs. 489-498.			
	A250	E. H. SZYBALSKA et al., "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait," Proc. Natl. Acad. Sci., Vol. 48 (1962), pgs. 2026-2034.			
	A251	E. HOCHULI et al., "New Metal Chelate Adsorbent Selective for Proteins and Peptides Containing Neighbouring Histidine Residues," Journal of Chromatography, Vol. 411, (1987), pgs. 177-184.			
	A252	E. S. WARD et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," NATURE, Vol. 341, Oct. 1989, pgs. 544-546.			
	A253	F. ARENZANA-SEISDEDOS et al., "HIV blocked by chemokine antagonist," NATURE, Vol. 383, Oct. 1996, pg. 400.			
	A254	F. COCCHI et al., "Identification of RANTES, MIP-alpha, and MIP-1-beta as the Major HIV-Suppressive Factors Produced by CD8+ T Cells," SCIENCE, Vol. 270, Dec. 15, 1995, pgs. 1811-1815.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
Sheet	13	of	30	Attorney Docket Number	075977-0122

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A255	F. GOLBERE-GARAPIN et al., "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells," J. Mol. Biol., Vol. 150, (1981), pgs. 1-14.			
	A256	F. L. GRAHAM et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," Virology, Vol. 52, No. 2, April 1973, pgs. 456-467.			
	A257	F. M. AUSUBEL et al., "Current Protocols in Molecular Biology," Vol. 1, (1999).			
	A258	F. M. AUSUBEL, "Current Protocols in Molecular Biology," (2008).			
	A259	F. MALIK et al., "Polyethylene Glycol (PEG)-modified Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity," Experimental Hematology, Vol. 20, No. 8, Sept. 1992, pgs. 1028-1035.			
	A260	F. RASTINEJAD et al., "Regulation of the Activity of a New Inhibitor of Angiogenesis by a Cancer Suppressor Gene," Cell, Vol. 56, Feb. 10, 1989, pgs. 345-355.			
	A261	F.M. AUSUBEL et al., "Current Protocols in Molecular Biology," Vol. 1, 1998 edition.			
	A262	G. A. BITTER et al., "Expression and Secretion Vectors for Yeast," Methods in Enzymology - Recombinant DNA, Vol. 153, Part D, (1987), pgs. 516-545.			
	A263	G. E. FRANCIS et al., "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques," International Journal of Hematology, Vol. 68 (1998), pgs. 1-18.			
	A264	G. F. CROUSE et al., "Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes," Molecular and Cellular Biology, Vol. 3, No. 2, Feb. 1983, pgs. 257-266.			
	A265	G. GIMENEZ-GALLEGOS et al., "Brain-Derived Acidic Fibroblast Growth Factor: Complete Amino Acid Sequence and Homologies," SCIENCE, Vol. 230, Dec. 20, 1985, pgs. 1385-1388.			
	A266	G. KÖHLER et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," NATURE, Vol. 256, August 7, 1975, pgs. 495-497.			
	A267	G. KÖHLER et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," Eur. J. Immunol., Vol. 6, (1976), pgs. 511-519.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	14	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A268	G. KÖHLER et al., "Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines," <i>Eur. J. Immunol.</i> , Vol. 6, (1976), pgs. 292-295.			T <sup>6</sup>
	A269	G. KÖHLER, "Immunoglobulin chain loss in hybridoma lines," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 77, No. 4, April 1980, pgs. 2197-2199.			
	A270	G. KÜTEMEIER et al., "Assembly of Humanized Antibody Genes from Synthetic Oligonucleotides Using a Single-Round PCR," <i>BioTechniques</i> , Vol. 17, No. 2, (1994), pgs. 242-246.			
	A271	G. L. BOULIANNE et al., "Production of functional chimaeric mouse/human antibody," <i>NATURE</i> , Vol. 312, Dec. 13, 1984, pgs. 643-646.			
	A272	G. L. DENARDO et al., "Comparison of 1,4,7,10-Tetraazacyclododecane-N,N',N",N"-tetraacetic acid (DOTA)-Peptide-ChL6, a Novel Immunoconjugate with Catabolizable Linker, to 2-Iminothiolane-2-[p-(Bromoacetamido)benzyl]-DOTA-ChL6 in Breast Cancer Xenografts," <i>Clinical Cancer Research</i> , Vol. 4, Oct. 1998, pgs. 2483-2490.			
	A273	G. LOPEZ-BERESTEIN, "Treatment of systemic Fungal Infections with Liposomal-Amphotericin B," <i>Liposomes in the Therapy of Infectious Diseases and Cancer</i> , (1989), pgs. 317-327.			
	A274	G. M. STUDNICKA et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," <i>Protein Engineering</i> , Vol. 7, No. 6, (1994), pgs. 805-814.			
	A275	G. PETERSEN et al., "Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries," <i>Mol. Gen. Genet.</i> , Vol. 249, (1995), pgs. 425-431.			
	A276	G. SIMMONS et al., "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist," <i>SCIENCE</i> , Vol. 276, April 11, 1997, pgs. 276-279.			
	A277	G. VAN HEEKE et al., "Expression of Human Asparagine Synthetase in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , Vol. 264, No. 10, April 1989, pgs. 5503-5509.			
	A278	G. WRIGHT et al., "High Level Expression of Active Human Alpha-1-Antitrypsin in the Milk of Transgenic Sheep," <i>Bio/Technology</i> , Vol. 9, Sept. 1991, pgs. 830-834.			
	A279	G. Y. WU et al., "Delivery systems for gene therapy," <i>Biotherapy</i> , Vol. 3, No. 1, (1991), pgs. 87-95.			
	A280	G. Y. WU et al., "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," <i>The Journal of Biological Chemistry</i> , Vol. 262, No. 10, April 1987, pgs. 4429-4432.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
Sheet	15	of	30	Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
	A281	H. BUCHWALD et al., "Long-term continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," SURGERY, Vol. 88, No. 4, Oct. 1980, pgs. 507-516.				
	A282	H. DOBELI et al., "Role of the carboxy-terminal sequence on the biological activity of human immune interferon (IFN- $\gamma$ )," Journal of Biotechnology, Vol. 7 (1988), pgs. 199-216.				
	A283	H. GU et al., "Deletion of a DNA Polymerase Beta Gene Segment in T Cells using Cell Type-Specific Gene Targeting," SCIENCE, Vol. 265, July 1, 1994, pgs. 103-106.				
	A284	H. HOHMANN et al., "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNF alpha)," The Journal of Biological Chemistry, Vol. 264, No. 25, Sept. 5, 1989, pgs. 14927-14934.				
	A285	H. K. SLUSS et al., "Signal Transduction by Tumor Necrosis Factor Mediated by JNK Protein Kinases," Molecular and Cellular Biology, Vol. 14, No. 12, Dec. 1994, pgs. 8376-8384.				
	A286	H. KIEM et al., "Retrovirus-Mediated Gene Transduction into Canine Peripheral Blood Repopulating Cells," Blood, Vol. 83, No. 6, March 1994, pgs. 1467-1473.				
	A287	H. LOETSCHER et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," Cell, vol. 61, April 20, 1990, pgs. 351-359.				
	A288	H. M GEYSEN et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," Proc. Natl. Acad. Sci. USA, Vol. 81, July 1984, pgs. 3998-4002.				
	A289	H. NISHIYAMA et al., "Homozygous Deletion at the 9q32-33 Candidate Tumor Suppressor Locus in Primary Human Bladder Cancer," Genes, Chromosomes & Cancer, Vol. 26 (1999), pgs. 171-175.				
	A290	H. OKANO et al., "Myelin Basic Protein Gene and the Function of Antisense RNA and its Repression in Myelin-Deficient Mutant Mouse," Journal of Neurochemistry, Vol. 56, No. 2, (1991), pgs. 560-567.				
	A291	H. P. FELL et al., "Genetic Construction and Characterization of a Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," The Journal of Immunology, Vol. 146, No. 7, April 1991, pgs. 2446-2452.				
	A292	H. SAWAI et al., "Direct Production of the Fab Fragment Derived from the Sperm Immobilizing Antibody Using Polymerase Chain Reaction and cDNA Expression Vectors," American Journal of Reproductive Immunology, Vol. 34, (1995), pgs. 26-34.				
	A293	H. TABATA et al., "Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA," Cardiovascular Research, Vol. 35, (1997), pgs. 470-479.				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
(use as many sheets as necessary)				Attorney Docket Number	075977-0122
Sheet	16	of	30		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A294	H. VAN DER PUTTEN et al., "Efficient insertion of genes into the mouse germ line via retroviral vectors," Proc. Natl. Acad. Sci. USA, Vol. 82, Sept. 1985, pgs. 6148-6152.	
	A295	H. VIE et al., "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA, Vol. 89, Dec. 1992, pgs. 11337-11341.	
	A296	I. LOWY et al., "Isolation of Transforming DNA: Cloning the Hamster aprt Gene," Cell, Vol 22, Dec. 1980, pgs. 817-823.	
	A297	I. WILMUT et al., "Viable offspring derived from fetal and adult mammalian cells," NATURE, Vol. 385, February 27, 1997, pgs. 810-813.	
	A298	I. WILSON et al., "The Structure of an Antigenic Determinant in a Protein," Cell, Vol. 37, July 1984, pgs. 767-778.	
	A299	J. J. B. BOESEN et al., "Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene," Biotherapy, Vol. 6, (1994), pgs. 291-302.	
	A300	J. A. CARLINO et al., "Use of a Sensitive Receptor Binding Assay to Discriminate Between Full-length and Truncated Human Recombinant Tumor Necrosis Factor Proteins," The Journal of Biological Chemistry, Vol. 262, No. 3, Jan. 25, 1987, pgs. 958-961.	
	A301	J. A. HARROP et al., "Antibodies to TR2 (Herpesvirus Entry Mediator), a New Member of the TNF Receptor Superfamily, Block T Cell Proliferation, Expression of Activation Markers, and Production of Cytokines," Journal of Immunology, Vol. 161, No. 4, (1998), pgs. 1786-1794.	
	A302	J. A. WELLS et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," GENE, Vol. 34 (1985), pgs. 315-323.	
	A303	J. A. WELLS et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin," Phil. Tran. R. Soc. Lond. A, Vol. 317 (1986), pgs. 415-423.	
	A304	J. B. ULMER et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," SCIENCE, Vol. 259, Mar. 19, 1993, pgs. 1745-1749.	
	A305	J. BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," SCIENCE, Vol. 247, March 16, 1990, pgs. 1306-1310.	
	A306	J. CHAO et al., "Experimental Kallikrein Gene therapy in Hypertension, Cardiovascular and Renal Diseases," Pharmacological Research, Vol. 35, No. 6, (1997), pgs. 517-522.	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	17	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A307	J. COLIGAN et al., "Isolation of T Cells Using Rosetting Procedures," Chapter 7.22 of Current Protocols in Immunology, Vol. 2, 1994 edition, pgs. 7.2.1-7.2.4.			
	A308	J. D. TAUROG et al., "Synergy Between Adjuvant Arthritis and Collagen-Induced Arthritis in Rats," J. Exp. Med., Vol. 162, Sept. 1985, pgs. 962-978.			
	A309	J. DENEKAMP, "Vascular attack as a therapeutic strategy for cancer," Cancer and Metastasis Reviews, Vol. 9, (1990), pgs. 267-282.			
	A310	J. FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease," NATURE MEDICINE, Vol. 1, No. 1, (1995), pgs. 27-31.			
	A311	J. FOLKMAN et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone," SCIENCE, Vol. 221, Aug. 19, 1983, pgs. 719-725.			
	A312	J. FOLKMAN et al., "Angiogenesis Regulation of Angiogenesis in Health & Disease," The Journal of Biological Chemistry, Vol. 267, No. 16, June 5, 1992, pgs. 10931-10934.			
	A313	J. FOLKMAN et al., "Angiogenic Factors," SCIENCE, Vol. 235, Jan. 23, 1987, pgs. 442-447.			
	A314	J. FOLKMAN, "Clinical Applications of Research on Angiogenesis," New England Journal of Medicine, Vol. 333, No. 26, (1995), pgs. 1757-1763.			
	A315	J. G. SUTCLIFFE et al., "Antibodies that React with Predetermined Sites on Proteins," SCIENCE, Vol. 219, (1983), pgs. 660-666.			
	A316	J. J. PETERSON et al., "Enzymatic Cleavage of Peptide-Linked Radiolabels from Immunoconjugates," Bioconjugate Chemistry, Vol. 10, No. 4, July/August 1999, pgs. 553-557.			
	A317	J. L. CLELAND et al., "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation," Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 10, No. 4, (1993), pgs. 307-377.			
	A318	J. LIAUTARD et al., "Specific Inhibition of IL-6 Signalling with Monoclonal Antibodies Against the gp130 Receptor," CYTOKINE, Vol. 9, No. 4, April 1997, pgs. 223-241.			
	A319	J. LOEFFLER et al., "Gene Transfer into Primary and Established Mammalian Cell Lines with Lipopolyamine-Coated DNA," Methods in Enzymology, Vol. 217, (1993), pgs. 598-619.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	18	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A320	J. LOGAN et al., "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," Proc. Natl. Acad. Sci. USA, Vol. 81, June 1984, pgs. 3655-3659.			T <sup>6</sup>
	A321	J. M. GOODSON, "Dental Applications," Medical Applications of Controlled Release, Volume II, (1984), pgs 115-138.			
	A322	J. NI et al., "Cystatin E is a Novel Human Cysteine Proteinase Inhibitor with Structural Resemblance to Family 2 Cystatins," The Journal of Biological Chemistry, Vol. 272, No. 16, April 18, 1997, pgs. 10853-10858.			
	A323	J. R. WANDS et al., "High Afinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HBsAg) Produced by Somatic Cell Hybrids," Gastroenterology, Vol. 80, No. 2, (1981), pgs. 225-232.			
	A324	J. RHEINWALD, "Serial Cultivation of Normal Human Epidermal Keratinocytes," Methods in Cell Biology, Vol. 21A, Chapter 15, (1980), pgs. 229-253.			
	A325	J. S. HUSTON et al., "Progein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli," Proc. Natl. Acad. Sci. USA, Vol. 85, August 1988, pgs. 5879-5883.			
	A326	J. S. HUSTON et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," Methods in Enzymology, Vol. 203, (1991), pgs. 46-88.			
	A327	J. S. LEE et al., "Complexes formed by (pyrimidine)n - (purine)nDNAs on lowering the pH are three-stranded," Nucleic Acids Research, Vol. 6, No. 9, (1979), pgs. 3073-3091.			
	A328	J. SAMBROOK et al., "Molecular Cloning - A Laboratory Manual," second edition, 1990.			
	A329	J. TREAT et al., "Liposome Encapsulated Doxorubicin Preliminary Results of Phase 1 and Phase II Trials," Liposomes in the Therapy of Infectious Diseases and Cancer, Proceedings of a Ciba-Geigy-Squibb-UCLA Colloquium, Feb. 16-20, 1988, pgs. 353-365.			
	A330	K. E. HELLSTROM et al., "Antibodies for Drug Delivery," Controlled Drug Delivery Fundamentals and Applications, second edition, (1987), pgs. 624-653.			
	A331	K. F. KOZARSKY et al., "Gene therapy: adenovirus vectors," Current Opinion in Genetics and Development, Vol. 3, (1993), pgs. 499-503.			
	A332	K. GASE et al., "Critical role of the C-terminus in the biological activities of human tumour necrosis factor-alpha," Immunology, Vol. 71, (1990), pgs. 368-371.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	19	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A333	K. H. S. CAMPBELL et al., "Sheep cloned by nuclear transfer from a cultured cell line," NATURE, Vol. 380, March 7, 1996, pgs. 64-66.			
	A334	K. MIURA et al., "Detailed Deletion Mapping in Squamous Cell Carcinomas of the Esophagus Narrows a Region Containing a Putative Tumor Suppressor Gene to about 200 Kilobases on Distal Chromosomes 9q1," Cancer Research, Vol. 56, April 1, 1996, pgs. 1629-1634.			
	A335	K. O'HARE et al., "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase," Proc. Natl. Acad. Sci. USA, Vol. 78, No. 3, March 1981, pgs. 1527-1531.			
	A336	K. THOMAS et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells," Cell, Vol. 51, Nov. 6, 1987, pgs. 503-512.			
	A337	K. ZIMMERMANN et al., "A Triglycine Linker Improves Tumor Uptake and Biodistributions of 67-Cu-Labeled Anti-Neuroblastoma MAb chCE7 F(ab')2 Fragments," Nuclear Medicine & Biology, Vol. 26, 1999, pgs. 943-950.			
	A338	L. G. DAVIS et al., "Methods in Molecular Biology," (1986).			
	A339	L. M. MARTINS et al., "Activation of Multiple Interleukin-1beta Converting Enzyme Homologues in Cytosol and Nuclei of HL-60 Cells during Etoposide-induced Apoptosis," The Journal of Biological Chemistry, Vol. 272, No. 11, March 14, 1997, pgs. 7421-7430.			
	A340	L. O. HANSSON et al., "Evolution of Differential Substrate Specificities in Mu Class Glutathione Transferases Probed by DNA Shuffling," J. Mol. Biol. Vol. 287 (1999), pgs 265-276.			
	A341	L. PERSIC et al., "An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries," Gene, Vol. 187 (1997), pgs. 9-18.			
	A342	L. RIECHMANN et al., "Reshaping human antibodies for therapy," NATURE, Vol. 332, March 1988, pgs. 323-327.			
	A343	L. S. JESPERS et al., "Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen," Bio/Technology, Vol. 12, Sept. 1994, pgs. 899-903.			
	A344	L. SCHWEIGERER et al., "Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth," NATURE, Vol. 325, Jan. 15, 1987, pgs. 257-259.			
	A345	L. SHU et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells," Proc. Natl. Acad. Sci. USA, Vol. 90, September 1993, pgs. 7995-7999.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	20	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A346	L. W. BURRUS et al., "Isolation of a Receptor for Acidic and Basic Fibroblast Growth Factor from Embryonic Chick," The Journal of Biological Chemistry, Vol. 264, No. 31, Nov. 5, 1989, pgs. 18647-18653.			T <sup>6</sup>
	A347	L. WU et al., "CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro," J. Exp. Med., Vol. 185, No. 9, May 5, 1997, pgs. 1681-1691.			
	A348	L. ZURFLUH et al., "Auxin-induced changes in the patterns of protein synthesis in soybean hypocotyl," Proc. Natl. Acad. Sci. USA, Vol. 77, No. 1, Jan. 1980, pgs. 357-361.			
	A349	M. A. HOWARD et al., "Interacerebral drug delivery in rats with lesion-induced memory deficits," J. Neurosurg, Vol. 71, July 1989, pgs. 105-112.			
	A350	M. A. MOSES et al., "Inhibitors of Angiogenesis," Bio/Technology, Vol. 9, July 1991, pgs. 630-634.			
	A351	M. A. ROGUSKA et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," Proc. Natl. Acad. Sci. USA, Vol. 91, Feb. 1994, pgs. 969-973.			
	A352	M. A. ROSENFIELD et al., "Adenovirus-Mediated Transfer of a Recombinant alpha-1-Antitrypsin Gene to the Lung Epithelium in Vivo," SCIENCE, Vol. 252, April 1991, pgs. 431-434.			
	A353	M. A. ROSENFIELD et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," Cell, Vol. 68, Jan. 1992, pgs. 143-155.			
	A354	M. BETTER et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," SCIENCE, Vol. 240, May 1988, pgs. 1041-1043.			
	A355	M. C. FISHMAN et al., Medicine, 2d Ed. J. B. Lippincott Co., (1985).			
	A356	M. CHOW et al., "Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies," Proc. Natl. Acad. Sci. USA, Vol. 82, Feb. 1985, pgs. 910-914.			
	A357	M. COONEY et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro," SCIENCE, Vol. 241, July 22, 1988, pgs. 456-459.			
	A358	M. COTTEN et al., "Receptor-Mediated Transport of DNA into Eukaryotic Cells," Methods in Enzymology, Vol. 217, (1993), pgs. 618-645.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	21	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A359	M. D. JACOBSON et al., "Role of Ced-3/ICE-Family Proteases in Staurosporine-induced Programmed Cell Death," The Journal of Cell Biology, Vol. 133, No. 5, June 1996, pgs. 1041-1051.		
	A360	M. D. SUMMERS et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," May, 1987, pgs. 1-56.		
	A361	M. del MAR LORENZO et al., "PCR-Based Method for the Introduction of Mutations in Genes Cloned and Expressed in Vaccinia Virus," BioTechniques, Vol. 24, No. 2 (1998), pgs. 308-313.		
	A362	M. FOUNTOULAKIS et al., "Interferon $\gamma$ Receptor Extracellular Domain Expressed as IgG Fusion Protein in Chinese Hamster Ovary Cells," The Journal of Biological Chemistry, Vol. 270, No. 8, Feb. 24, 1995, pgs. 3958-3964.		
	A363	M. GROSSMAN et al., "Retroviruses: delivery vehicle to the liver," Current Opinion in Genetics and Development, Vol. 3, (1993), pgs. 110-114.		
	A364	M. HAHNE et al., "April, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," J. Exp. Med., Vol. 168, No. 6, Sept. 21, 1988, pgs. 1185-1190.		
	A365	M. I. COCKETT et al., "High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells using Glutamine Synthetase Gene Amplification," Bio/Technology, Vol. 8, July 1990, pgs. 662-667.		
	A366	M. J. DURING et al., "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," Annals of Neurology, Vol. 25, No. 4, April 1989, pgs. 351-356.		
	A367	M. J. FRANCIS et al., "Immunological Priming with Synthetic Peptides of Foot-and-Mouth Disease Virus," J. Gen. Virol., Vol. 66 (1985), pgs. 2347-2354.		
	A368	M. J. ZOLLER et al., "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," Nucleic Acids Research, vol. 10, No. 20, (1982), pgs. 6487-6500.		
	A369	M. JALKANEN et al., "Cell Surface Proteoglycan of Mouse Mammary Epithelial Cells is Shed by Cleavage of its Matrix-binding Ectodomain from its Membrane-associated Domain," The Journal of Cell Biology, Vol. 105, (No. 6, Pt. 2), Dec. 1987, pgs 3087-3096.		
	A370	M. JALKANEN et al., "Heparan Sulfate Proteoglycans from Mouse Mammary Epithelial Cells: Localization on the Cell Surface with a Monoclonal Antibody," The Journal of Cell Biology, Vol. 101, Sept. 1985, pgs. 976-984.		
	A371	M. K. FOECKING et al., "Powerful and versatile enhancer-promoter unit for mammalian expression vectors," GENE, Vol. 45 (1986), pgs. 101-105.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	22	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A372	M. KOZAK, "Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo," NATURE, Vol. 308, March 15, 1984, pgs. 241-246.			
	A373	M. KRIEGLER, "Gene Transfer and Expression - A Laboratory Manual," (1990).			
	A374	M. L. IRUELA-ARISPE et al., "Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors," Thrombosis and Haemostasis, (1997), pgs. 672-677.			
	A375	M. LAKSO et al., "Targeted oncogene activation by site-specific recombination in transgenic mice," Proc. Natl. Acad. Sci. USA, Vol. 89, July 1992, pgs. 6232-6236.			
	A376	M. LAVITRANO et al., "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice," Cell, Vol. 57, June 2, 1989, pgs. 717-723.			
	A377	M. M. CLOWES et al., "Long-Term Biological Response of Injured Rat Carotid Artery Seeded with Smooth Muscle Cells Expressing Retrovirally Introduced Human Genes," J. Clin. Invest., Vol. 93, Feb. 1994, pgs. 644-651.			
	A378	M. MORPURGO et al., "Covalent Modification of Mushroom Tyrosinase with Different Amphiphic Polymers for Pharmaceutical and Biocatalysis Applications," Applied Biochemistry and Biotechnology, Vol. 56, (1996), pgs. 59-72.			
	A379	M. NARAMURA et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells," Immunology Letters, Vol. 39, (1994), pgs. 91-99.			
	A380	M. NGUYEN et al., "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," Microvascular Research, Vol. 47, (1994), pgs. 31-40.			
	A381	M. O'REILLY et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell, Vol. 88, Jan. 24, 1997, pgs. 277-285.			
	A382	M. PRAT et al., "Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF," Journal of Cell Science, Vol. 111 (1998), pgs. 237-247.			
	A383	M. R. PITTELKOW et al., "New Techniques for the In Vitro Cultrue of Human Skin Keratinocytes and Perspectives on Their Use for Grafting of Patients with Extensive Burns," Mayo Clin. Proc., Vol. 61, (1986), pgs. 771-777.			
	A384	M. S. NEUBERGER et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," NATURE, Vol. 314, March 21, 1985, pgs. 268-270.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	23	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A385	M. S. NEUBERGER et al., "Recombinant antibodies possessing novel effector functions," NATURE, Vol. 312, Dec. 1984, pgs. 604-608.		
	A386	M. S. O'REILLY et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, Vol. 79, October 21, 1994, pgs. 315-328.		
	A387	M. V. SEFTON, "Implantable Pumps," Critical Reviews in Biomedical Engineering, Vol. 14, Issue 3, (1987), pgs. 201-240.		
	A388	M. VERHEIJ et al., "Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis," NATURE, Vol. 380, March 7, 1996, pgs. 75-79.		
	A389	M. WIGLER et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells," Cell, Vol. 11, May 1977, pgs. 223-232.		
	A390	M. WOO et al., "Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes," Genes & Development, Vol. 12, (1998), pgs. 806-819.		
	A391	M. ZIJLSTRA et al., "Germ-line transmission of a disrupted Beta-2-microglobulin gene produced by homologous recombination in embryonic stem cells," NATURE, Vol. 342, Nov. 23, 1989, pgs. 435-438.		
	A392	N. A. THORNBERRY et al., "A novel heterodimeric cysteine protease is required for interleukin-1 $\beta$ processing in monocytes," NATURE, Vol. 356, April 30, 1992, pgs. 768-774.		
	A393	N. CARLSON et al., "Identification of Amino Acids in the Glutamate Receptor, GluR3, Important for Antibody-binding and Receptor-specific Activation," The Journal of Biological Chemistry, Vol. 272, No. 17, April 25, 1997, pgs. 11295-11301.		
	A394	N. J. PROUDFOOT, "Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation," NATURE, Vol. 322, August 1986, pgs. 562-565.		
	A395	N. LONBERG et al., "Human Antibodies from Transgenic Mice," Intern. Rev. Immunol., Vol. 13, (1995), pgs. 65-93.		
	A396	N. S. GREENSPAN et al., "Idiotypes: Structure and immunogenicity," The FASEB Journal, Vol. 7, March 1993, pgs. 437-444.		
	A397	O. SMITHIES et al., "Insertion of DNA sequences into the human chromosomal Beta-globin locus by homologous recombination," NATURE, Vol. 317, Sept. 19, 1985, pgs. 230-234.		

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
(use as many sheets as necessary)				Attorney Docket Number	075977-0122
Sheet	24	of	30		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
	A398	P. A. PATTEN et al., "Applications of DNA shuffling to pharmaceuticals and vaccines," Pharmaceutical Biotechnology, Vol. 8 (1997), pgs. 724-733.				
	A399	P. BARTUNVEK et al., "Avian Stem Cell Factor (SCF): Production and Characterization of the Recombinant HIS-Tagged SCF of Chicken and its Neutralizing Antibody," CYTOKINE, Vol. 8, No. 1, Jan. 1996, pgs. 14-20.				
	A400	P. C. BROOKS et al., "Integrin alpha-v-beta-3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," Cell, Vol. 79, Dec. 30, 1994, pgs. 1157-1164.				
	A401	P. CALICETI et al., "Biopharmaceutical Properties of Uricase Conjugated to Neutral and Amphiphilic Polymers," Bioconjugate Chem., No. 10 (1999), pgs. 638-646.				
	A402	P. CARTER et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors," Nucleic Acids Research, Vol. 13, No. 12, (1985), pgs. 4431-4443.				
	A403	P. CHOMCZYNSKI et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," Analytical Biochemistry, Vol. 162, (1987), pgs. 156-159.				
	A404	P. E. THORPE et al., "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates," Immunological Rev., Vol. 62, (1982), pgs. 119-158.				
	A405	P. E. VOROJJEV et al., "Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNase H," Nucleosides and Nucleotides, Vol. 18 (1999), pgs. 2745-2750.				
	A406	P. FELGNER et al., "Improved Cationic Lipid formulations for In Vivo Gene Therapy," Annals NY Academy of Sciences, Vol. 772, (1995), pgs. 126-139.				
	A407	P. FORRER et al., "Enzyme-Linked Immunosorbent Assay for Measurement of JNK, ERK, and p38 Kinase Activities," Biol. Chem., Vol. 379, Aug/Sept. 1998, pgs. 1101-1111.				
	A408	P. JUO et al., "Fas Activation of the p38 Mitogen-Activated Protein Kinase Signalling Pathway Requires ICE/CED-3 Family Proteases," Molecular and Cellular Biology, Vol. 17, No. 1, Jan. 1997, pgs. 24-35.				
	A409	P. KIRSCHMEIER et al., "Laboratory Methods - Construction and Characterization of a Retroviral Vector Demonstrating Efficient Expression of Cloned cDNA Sequences," DNA, Vol. 7, No. 3, (1988), pgs. 219-225.				
	A410	P. L. FELGNER et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proc. Natl. Acad. Sci. USA, Vol. 84, Nov. 1987, pgs. 7413-7417.				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	25	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A411	P. TOLSTOSHEV, "Gene Therapy, Concepts, Current Trials and Future Directions," Ann. Rev. Pharmacol. Toxicol., Vol. 32, (1993), pgs. 573-596.		
	A412	Q. WANG et al., "A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions," Gene Therapy, Vol. 2, (1995), pgs. 775-783.		
	A413	R. A. HOUGHTEN, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," Proc. Natl. Acad. Sci. USA, Vol. 82, August 1985, pgs. 5131-5135.		
	A414	R. A. MORGAN et al., "Human Gene Therapy," Annu. Rev. Biochem., Vol. 62, (1993), pgs. 191-217.		
	A415	R. ARNON et al., "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy," Monoclonal Antibodies and Cancer Therapy, (1985), pgs. 243-256.		
	A416	R. C. MULLIGAN et al., "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase," Proc. Natl. Acad. Sci. USA, Vol. 78, No. 4, April 1981, pgs. 2072-2076.		
	A417	R. C. MULLIGAN, "The Basic Science of Gene Therapy," SCIENCE, Vol. 260, May 1993, pgs. 926-932.		
	A418	R. COTTON et al., "Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study mutations," Proc. Natl. Acad. Sci. USA, Vol. 85, June 1988, pgs. 4397-4401.		
	A419	R. E. BIRD et al., "Single-Chain Antigen-Binding Proteins," SCIENCE, Vol. 242, Oct. 1988, pgs. 423-426.		
	A420	R. F. SANTERRE et al., "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells," Gene, Vol. 30 (1984), pgs 147-156.		
	A421	R. GENTZ et al., "Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: Trans-activation requires mRNA synthesis," Proc. Natl. Acad. Sci. USA, Vol. 86, Feb. 1989, pgs. 821-824.		
	A422	R. JANKNECHT et al., "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus," Proc. Natl. Acad. Sci. USA, Vol. 88, Oct. 1991, pgs. 8972-8976.		
	A423	R. KAMIJO et al., "Induction of Differentiation of Human Monoblastic and Myeloblastic Leukemia Cell Lines by TNF Muteins," Biochemical and Biophysical Research Communications, Vol. 160, No. 2, 1989, pgs. 820-827.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
Sheet	26	of	30	Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A424	R. L. MULLINAX et al., "Expression of a Heterodimeric Fab Antibody Protein in One Cloning Step," Biotechniques, Vol. 12, No. 6, (1992), pgs. 864-869.		
	A425	R. LANGER et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," Rev. Macromol. Chem. Phys., Vol. C23, No. 1, (1983), pgs. 61-126.		
	A426	R. LANGER, "New Methods of Drug Delivery," SCIENCE, Vol. 249, Sept. 1990, pgs. 1527-1533.		
	A427	R. LEVY et al., "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," SCIENCE, Vol. 228, April, 1985, pgs. 190-192.		
	A428	R. MYERS et al., "Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA:DNA Duplexes," SCIENCE, Vol. 230, Dec. 13, 1985, pgs. 1242-1246.		
	A429	R. N. PINCKARD et al., "Factors Influencing the Immune Response," Clin. exp. Immunol., Vol. 2 (1967), pgs. 331-341.		
	A430	R. S. AMES et al., "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins," Journal of Immunological Methods, Vol. 184 (1995), pgs. 177-186.		
	A431	R. S. LANGER et al., "Medical Applications of Controlled Release," CRC Press, Boca Raton, FL (1974).		
	A432	R. S. SIDHU et al., "Tumor Necrosis Factor Analogs: Identification of Functional Domains," Anticancer Research, Vol. 9, No. 6, Nov.-Dec. 1989, pgs. 1569-1576.		
	A433	R. S. VERMA et al., "Human Chromosomes, Manual of Basic Technique, (1988).		
	A434	R. SAIKI et al., "Analysis of enzymatically amplified Beta-globin and HLA-DQ-alpha DNA with allele-specific oligonucleotide probes," NATURE, Vol. 324, Nov. 13, 1986, pgs. 163-166		
	A435	R. TWYMAN et al., "Glutamate Receptor Antibodies Activate a Subset of Receptors and Reveal an Agonist Binding Site," Neuron, Vol. 14, April 1995, pgs. 755-762.		
	A436	R. V. TALANIAN et al., "Substrate specificities of Caspase Family Proteases," The Journal of Biological Chemistry, Vol. 272, No. 15, April 11, 1997, pgs. 9677-9682.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	27	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A437	S. A. KOSTELNY et al., "Formation of a Bispecific Antibody by the use of Leucine Zippers," The Journal of Immunology, Vol. 148, No. 5, March 1, 1992, pgs. 1547-1553.			T <sup>6</sup>
	A438	S. ANDERSON et al., "Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme," The Journal of Biological Chemistry, Vol. 264, No. 14, May 15, 1989, pgs. 8222-8229.			
	A439	S. BURCHIEL et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments," Tumor Imaging - The Radioimmunochemical Detection of Cancer, Chapter 13, (1982), pgs. 125-139.			
	A440	S. D. GILLIES et al., "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells," Proc. Natl. Acad. Sci. USA, Vol. 89, Feb. 1992, pgs. 1428-1432.			
	A441	S. E. ORDER, "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy," Monoclonal Antibodies for Cancer Detection and Therapy, Academic Press, (1982), pages 303-316.			
	A442	S. GARTNER et al., "Neovascularization of the Iris (Rubeosis Iridis), Survey of Ophthalmology, Vol. 22, No. 5, March-April 1978, pgs. 291-312.			
	A443	S. HAUSER et al., "A Heparin-Binding Form of Placenta Growth Factor (P1GF-2) is Expressed in Human Umbilical Vein Endothelial Cells and in Placenta," Growth Factors, Vol. 9, (1993), pgs. 259-268.			
	A444	S. INOUYE et al., "Up-promoter mutations in the lpp gene of Escherichia coli," Nucleic Acids Research, Vol. 13, No. 9, (1985), pgs. 3101-3110.			
	A445	S. J. MORRISON et al., "Prospective Identification, Isolation by Flow Cytometry, and In Vivo Self-Renewal of Multipotent Mammalian Neural Crest Stem Cells," Cell, Vol. 96, March 1999, pgs. 737-749.			
	A446	S. J. POLLACK et al., "Introduction of Nucleophiles and Spectroscopic Probes into Antibody Combining Sites," SCIENCE, Vol. 242, Nov. 1988, pgs. 1038-1040.			
	A447	S. KUMAR et al., "Activation of the HIV-1 Long Terminal Repeat by Cytokines and Environmental Stress Requires an Active CSBP/p38 MAP Kinase," The Journal of Biological Chemistry, Vol. 271, No. 48, Nov. 29, 1996, pgs. 30864-30869.			
	A448	S. L. MORRISON et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA, Vol. 81, Nov. 1984, pgs. 6851-6855.			
	A449	S. L. MORRISON, "Transfectomas Provide Novel Chimeric Antibodies," SCIENCE, Vol. 229, September 1985, pgs. 1202-1207.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
(use as many sheets as necessary)				Attorney Docket Number	075977-0122
Sheet	28	of	30		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
	A450	S. NAGATA et al., "The Fas Death Factor," SCIENCE, Vol. 267, March 10, 1995, pgs. 1449-1456.				
	A451	S. SINGH et al., "Activation of Transcription of Factor NF- $\kappa$ B is Suppressed by Curcumin (Diferuloylmethane)," The Journal of Biological Chemistry, Vol. 270, No. 42, Oct. 1995, pgs. 24995-25000.				
	A452	S. SINGH et al., "Protein-tyrosine Phosphatase Inhibitors Block Tumor nNecrosis Factor-dependent Activation of the Nuclear Transcription Factor NF- $\kappa$ B," The Journal of Biological Chemistry, vol. 270, No. 18, May 1995, pgs. 10631-10639.				
	A453	S. TAKEDA et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," NATURE, Vol. 314, April 1985, pgs. 452-454.				
	A454	S. THOMPSON et al., "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells," Cell, Vol. 56, January 27, 1989, pgs. 313-321.				
	A455	S. WENNSTRÖM et al., "cDNA Cloning and Expression of a Human FGF Receptor which Binds Acidic and Basic FGF," Growth Factors, Vol. 4, (1991), pgs. 197-208.				
	A456	T. A. BIBILA et al., "In Pursuit of the Optimal Fed-Batch Process for Monoclonal Antibody Production," Biotechnol. Prog., Vol. 11, No. 1, (1995), pgs. 1-13.				
	A457	T. A. HOLTON et al., "A simple and efficient method for direct cloning of PCR products using ddT-tailed vectors," Nucleic Acids Research, Vol. 19, No. 5, (1991), pg. 1156.				
	A458	T. HABUCHI et al., "A novel candidate tumor suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC," Human Molecular Genetics, Vol. 6, No. 6, (1997), pgs. 913-919.				
	A459	T. HABUCHI et al., "Structure and Methylation-Based Silencing of a Gene (DBCCR1) within a Candidate Bladder Cancer Tumor Suppressor Region at 9q32-q33," Genomics, Vol. 48, (1998), pgs. 277-288.				
	A460	T. HIRANO et al., "Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin," NATURE, Vol. 324, Nov. 1986, pgs. 73-76.				
	A461	T. MAIONE et al., "Inhibition of Angiogenesis by Recombinant Human Platelet Factor - 4 and Related Peptides," Science, Vol. 247, Jan. 5, 1990, pgs. 77-79.				
	A462	T. NISHIWAKI et al., "Isolation and Mutational Analysis of a Novel Human cDNA, DECI (Deleted in Esophageal Cancer I), Derived from the Tumor Suppressor Locus in 9q32," Genes, Chromosomes & Cancer, Vol. 27, (2000), pgs. 169-176.				

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 29 of 30

**Complete if Known**

Application Number	09/899059
Filing Date	07/06/2001
First Named Inventor	Craig A. Rosen
Art Unit	1647
Examiner Name	Guo-Liang Yu

Attorney Docket Number 075977-0122

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A463	T. PATERSON et al., "Approaches to maximizing stable expression of alpha-1-antitrypsin in transformed CHO cells," Appl. Microbiol. Biotechnol., Vol. 40, (1994), pgs. 691-698.	
	A464	T. SMITH et al., "Comparison of Biosequences," Advances in Applied Mathematics, Vol. 2, (1981), pgs. 482-489.	
	A465	T. YUE et al., "2-Methoxyestradiol, an Endogenous Estrogen Metabolite, Induces Apoptosis in Endothelial Cells and Inhibits Angiogenesis: Possible Role for Stress-Activated Protein Kinase Signaling Pathway and Fas Expression," Molecular Pharmacology, Vol. 51, (1997), pgs. 951-962.	
	A466	T. YUE et al., "Strausporine-induced Apoptosis in Cardiomyocytes: A Potential Role of Caspase-3," J. Mol. Cell Cardiol., Vol. 30, (1998), pgs. 495-507.	
	A467	U. BRINKMANN et al., "Phage display of disulfide-stabilized Fv fragments," Journal of Immunological Methods, Vol. 182 (1995), pgs. 41-50.	
	A468	U. RÜTHER et al., "Easy identification of cDNA clones," The EMBO Journal, Vol. 2, No. 10, (1983), pgs. 1791-1794.	
	A469	V. A. POLUNOVSKY et al., "Induction of Endothelial Cell Apoptosis by TNF-alpha: Modulation by Inhibitors of Protein Synthesis," Experimental Cell Research, Vol. 214, (1994), pgs. 584-594.	
	A470	V. F. SMOLEN et al., "Controlled Drug Bioavailability," Drug Product Design and Performance, Vol. 1, John Wiley & Sons, (1984).	
	A471	V. MCKUSICK et al., "Mendelian Inheritance of Man," A Catalog of Human Genes and Genetic Disorders, The Johns Hopkins University, Vol. 3, (1998).	
	A472	V. PITARD et al., "Production and characterization of monoclonal antibodies against the leukemia inhibitory factor low affinity receptor, gp190," Journal of Immunological Methods, Vol. 205 (1997), pgs. 177-190.	
	A473	V. T. OI et al., "Chimeric Antibodies," BioTechniques, Vol. 4, No. 3 (1986), pgs. 214-221.	
	A474	X. WANG et al., "Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis," The EMBO Journal, Vol. 15, No. 5, (1996), pgs. 1012-1020.	
	A475	X. X. ZHENG et al., "Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharide-Induced Septic Shock and Allogeneic Islet Transplantation," The Journal of Immunology, Vol. 154, (1995), pgs. 5590-5600.	

Examiner Signature	Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	30	of	30	Application Number	09/899059
				Filing Date	07/06/2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Guo-Liang Yu
				Attorney Docket Number	075977-0122

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A476	Y. GLUZMAN, "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants," Cell, Vol. 23, Jan. 1981, pgs. 175-182.		
	A477	Y. LI et al., "Use of Green Fluorescent Protein in Studies of Apoptosis of Transfected Cells," BioTechniques, Vol. 23, No. 6, (1997), pgs. 1026-1028.		
	A478	Y. TSURUMI et al., "Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion., Circulation, Vol. 94, No. 12, Dec. 15, 1996, pgs. 3281-3290.		
	A479	Y.A. MULLER et al., "VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface," Structure, Vol. 6, No. 9, (1998), pgs. 1153-1167.		
	A480	Z. CHEN et al., "Effects of Interleukin-1alpha, Interleukin-1 Receptor Antagonist, and Neutralizing Antibody on Proinflammatory Cytokine Expression by Human Squamous Cell Carcinoma Lines," Cancer Research, Vol. 58, Aug. 15, 1998, pgs. 3668-3676.		
	A481	Z. XIA et al., "Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis," SCIENCE, Vol. 270, Nov. 24, 1995, pgs. 1326-1331.		
	A482	Z. ZHU et al., "Inhibition of Vascular Endothelial Growth Factor-induced Receptor Activation with Anti-Kinase Insert Domain-containing Receptor Single-Chain Antibodies from a Phage Display Library," Cancer Research, Vol. 58, August 1998, pgs.3209-3214.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.